Chronic subdural hematomas account for over 90,000 hospitalizations annually and are projected to become the most common neurosurgical condition by 2030. Current interventions--including surgery and ...
HOUSTON--(BUSINESS WIRE)--Spark Biomedical and Velentium Medical, longtime partners in neuromodulation device development, today announced their partnership in the launch of OhmBody™, a division of ...
DALLAS, TX, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical Launches Telehealth Services for Sparrow Ascent, Improving Patient Access to Opioid Withdrawal Treatment August 8, 2023, Dallas, TX ...
Spark Biomedical’s Co-founder & Chief Science Officer, Dr. Navid Khodaparast, Ph.D., shared, “Completing enrollment marks a critical milestone in advancing transcutaneous auricular neurostimulation as ...
Dallas, TX, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Spark Biomedical, a leading developer of wearable neurostimulation devices, proudly announces the recent achievement of ISO 13485:2016 and MDSAP Quality ...
This trial will test the feasibility of wearable neurostimulation to help reduce fatal disorientation-related errors in the military. Dallas, TX, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Spark Biomedical, a ...
DALLAS, Texas, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aug. 29, 2023 — Spark Biomedical, Inc., a Dallas-based pioneer in wearable neurostimulation technology, was awarded a $1.15M Phase II grant to develop ...